Guggenheim Capital LLC Alkermes Plc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 90,994 shares of ALKS stock, worth $2.87 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

90,994

Previous 107,255 15.16%

Holding current value

$2.87 Million

Previous $2.58 Million 1.47%

% of portfolio

0.02%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$23.01 - $28.55 $374,165 - $464,251	-16,261 Reduced 15.16%	90,994 $2.55 Million
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $272,485 - $319,797	11,740 Added 12.29%	107,255 $2.58 Million
Q1 2024 May 14, 2024	BUY	$26.4 - $32.56 $444,998 - $548,831	16,856 Added 21.43%	95,515 $2.59 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $52,278 - $64,157	2,237 Added 2.93%	78,659 $2.18 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $283,274 - $333,319	10,426 Added 15.8%	76,422 $2.14 Million
Q2 2023 Aug 11, 2023	SELL	$28.34 - $33.63 $370,658 - $439,846	-13,079 Reduced 16.54%	65,996 $2.07 Million
Q1 2023 May 10, 2023	BUY	$25.31 - $29.02 $2 Million - $2.29 Million	79,075 New	79,075 $2.23 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $1.8 Million - $2.69 Million	-83,866 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $1.96 Million - $2.69 Million	83,866 New	83,866 $2.59 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $334,517 - $426,184	-18,370 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$15.39 - $22.1 $1.82 Million - $2.61 Million	-117,975 Reduced 86.53%	18,370 $366,000
Q3 2020 Nov 13, 2020	SELL	$16.16 - $20.66 $1.05 Million - $1.35 Million	-65,168 Reduced 32.34%	136,345 $2.26 Million
Q2 2020 Aug 14, 2020	BUY	$13.31 - $19.41 $972,215 - $1.42 Million	73,044 Added 56.86%	201,513 $3.91 Million
Q1 2020 Jun 02, 2020	SELL	$13.06 - $21.24 $392,322 - $638,049	-30,040 Reduced 18.95%	128,469 $1.85 Million
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $839,412 - $1.06 Million	48,549 Added 44.15%	158,509 $3.23 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $611,755 - $761,323	-31,356 Reduced 22.19%	109,960 $2.15 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $614,578 - $1.07 Million	28,625 Added 25.4%	141,316 $3.19 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $226,859 - $291,482	7,988 Added 7.63%	112,691 $4.11 Million
Q4 2018 Feb 14, 2019	SELL	$27.94 - $44.61 $252,018 - $402,382	-9,020 Reduced 7.93%	104,703 $3.09 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $518,398 - $619,391	13,430 Added 13.39%	113,723 $4.83 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $592,987 - $750,883	14,620 Added 17.06%	100,293 $4.13 Million
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $169,407 - $212,541	3,160 Added 3.83%	85,673 $4.97 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $1.73 Million - $2.01 Million	-36,360 Reduced 30.59%	82,513 $4.52 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $5.84 Million - $6.47 Million	118,873	118,873 $6.04 Million

Others Institutions Holding ALKS

# of Institutions

359

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.18B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Alkermes Plc. Transaction History